SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: lwd who wrote (6520)3/5/1999 10:32:00 AM
From: Vector1  Read Replies (1) of 9719
 
LWD,
The inter-company issues bother me. How do they determine the price and the terms. Henry negotiates with Henry. On the other hand it is clearly the right move. GTR does not have the resources to fund Diacrin and selling it will cut the burn significantly. GENZ has benefited from the tax shelter provided by the Diacrin losses. Hopefully that will be factored into the price.
Bottom line is that it comes down to the price. The market cap is so low that cash plus milestone payments in excess of $30m will result in a nice percentage gain.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News